Results

361 - 370 of 376 results for ‘guidelines’.

  • 14. Mpox (orthopoxvirus)

    http://corporat-prod.sites.silverstripe.com/for-health-professionals/clinical-guidance/immunisation-handbook/14-mpox

    ... Two doses of MPV are recommended, particularly for individuals with immunocompromise including well-controlled HIV infection, regardless of smallpox (vaccinia) vaccination history. 14.6. Contraindications and precautions See also section  ‎ 2.1.3 for pre-vaccination screening guidelines and section  ‎ 2.1.4 for general contraindications for all vaccines. Expand all 14.6.1. Contraindications 14.6.1. Contraindications MPV is contraindicated for anyone with a severe systemic allergic reaction (anaphylaxis) to a previous dose or any component of the vaccine, including ...

  • 12. Measles

    http://corporat-prod.sites.silverstripe.com/for-health-professionals/clinical-guidance/immunisation-handbook/12-measles

    Key information Mode of transmission Airborne spread or by direct contact with nasal or throat secretions of cases. Measles is one of the most highly communicable of all infectious diseases (R0=12–18). Incubation period About 10 days but may be 7–18 days from exposure to onset of fever and 14 days (7-21 days) to onset of rash. The incubation period may be longer in those given IG after exposure. Period of communicability From 4 days before to 4 days after rash onset, counting the day of rash onset as day 0 (ie. a total of 9 days). Incidence and burden of disease New Zealand was declared fr

  • 25. Zoster (herpes zoster/shingles)

    http://corporat-prod.sites.silverstripe.com/for-health-professionals/clinical-guidance/immunisation-handbook/25-zoster-herpes-zostershingles

    ... to three months for the use of rZV in individuals who are immunocompromised with an increased risk of zoster recurrence or prior to planned immunosuppression.  25.6. Contraindications and precautions See   section 2.1.3 (external link)   for pre-vaccination screening guidelines and   section 2.1.4   for general contraindications for all vaccines. Expand all 25.6.1. Contraindications 25.6.1. Contraindications Recombinant rZV (Shingrix) is contraindicated to individuals with a history of hypersensitivity to a previous dose or to any component of the va ...

  • 16. Pertussis (whooping cough)

    http://corporat-prod.sites.silverstripe.com/for-health-professionals/clinical-guidance/immunisation-handbook/16-pertussis-whooping-cough

    ... adults with a medical condition, not eligible for funded vaccine, who are at increased risk of severe consequences of pertussis (eg, those with chronic respiratory disease). 16.6. Contraindications and precautions See also   section 2.1.3   for pre-vaccination screening guidelines and   section 2.1.4 (external link)   for general contraindications for all vaccines. Expand all 16.6.1. Contraindications 16.6.1. Contraindications The only contraindication is an immediate severe anaphylactic reaction to the vaccine, or any component of the vaccine, followin ...

  • 17. Pneumococcal disease

    http://corporat-prod.sites.silverstripe.com/for-health-professionals/clinical-guidance/immunisation-handbook/17-pneumococcal-disease

    ... be considered in individuals at the very high risk of IPD who were not vaccinated prior to pregnancy.[ 71 ] PCV13 and 23PPV may be given to breastfeeding women.[ 71 (external link) ] 17.6. Contraindications and precautions See   section 2.1.3   for pre-vaccination screening guidelines and   section 2.1.4 (external link)   for general contraindications for all vaccines. Expand all 17.6.1. Contraindications 17.6.1. Contraindications There are no specific contraindications to pneumococcal polysaccharide or conjugate vaccines apart from a severe reaction to a ...

  • Information for Industry

    http://corporat-prod.sites.silverstripe.com/health-services-and-programmes/infrastructure-and-investment/information-for-industry

    The Investment and Infrastructure Group (IIG) at Health NZ is committed to ensuring the best possible outcomes for new health infrastructure projects, and the redevelopment and maintenance of current facilities. Good infrastructure enables our health workforce to deliver patient care safely and effectively. In delivering these objectives we need to work in partnership with the construction sector and positively contribute to building capacity and capability through the delivery of healthcare construction projects. This includes the provision of professional services, construction and related w

  • Nicotine replacement therapy

    http://corporat-prod.sites.silverstripe.com/for-health-providers/claims-provider-payments-and-entitlements/nicotine-replacement-therapy

    About the Nicotine Replacement Therapy (NRT) programme The Nicotine Replacement Therapy (NRT) programme is a scheme funded by the Public Health Directorate of the Ministry of Health. Reducing tobacco consumption is a high priority for the New Zealand Government. The priority given to reducing tobacco consumption is based on: the negative impact that tobacco use has on the health status of the population the associated costs to society the public demand for tobacco control the effectiveness of different strategies to reduce tobacco consumption, in particular NRT in combination with counselling.

  • SNOMED International

    http://corporat-prod.sites.silverstripe.com/health-services-and-programmes/digital-health/snomed-ct-national-release-centre/snomed-international

    About SNOMED International New Zealand is one of nine founder members of the International Health Terminology Standards Development Organisation (IHTSDO), the not-for-profit organisation established in 2007 that is now known as   SNOMED International (external link) . The purpose of SNOMED International is to own, develop and administer SNOMED CT and related terminology products, and to support the adoption of SNOMED CT in member countries and around the world. SNOMED International is a distributed organisation with its headquarters in London. The organisation is owned and gover

  • Testing adults for HIV in healthcare settings

    http://corporat-prod.sites.silverstripe.com/for-health-professionals/clinical-guidance/diseases-and-conditions/hiv-and-aids/testing-adults-for-hiv-in-healthcare-settings

    Human Immunodeficiency Virus (HIV) can be transmitted through condomless vaginal and anal sex, sharing needles, through pregnancy, childbirth and breastfeeding, and direct blood-to-blood contact with someone living with HIV. Without treatment, HIV causes a chronic progressive immune deficiency, leading to Acquired Immunodeficiency Syndrome (AIDS). There is no cure for HIV, but for those living with HIV in New Zealand (regardless of residency status), excellent treatment is available and funded. With early and effective treatment, people with HIV will stay well and will not progress to AIDS. Wi

  • Assisted dying resources, guidance and information for health professionals

    http://corporat-prod.sites.silverstripe.com/health-services-and-programmes/assisted-dying-service/information-for-health-professionals/assisted-dying-resources-guidance-and-information-for-health-professionals

    Responding when a person raises assisted dying: conversation guide and handbook It is important health professionals are prepared to respond with respect and compassion if assisted dying is raised by a person, regardless of personal views. The conversation guide and accompanying handbook, aim to support registered health professionals to respond appropriately and respectfully if a person raises assisted dying with them. These resources are designed to support health professionals when responding to an initial request. They are not intended to be used to assess a person’s eligibility. It cont